During this segment, Daniel J. George, MD, and Jeffrey Weber, MD, PhD, explore recently approved immunotherapy agents for the treatment of cancer.
Dr George briefly explains how sipuleucel-T and ipilimumab utilize the body’s immune system to fight disease. Dr George continues by explaining how these agents have demonstrated improvements in survival for patients with prostate cancer and melanoma. Furthermore, when looking at the expensive costs of treatment, the benefits make therapy more of an “investment” than an expense.
Dr Weber explains that sipuleucel-T is a vaccine, while ipilimumab is a checkpoint protein inhibitor. Then, he discusses the differences between these agents and how they work.
As Dr George and Dr Weber examine the safety profiles of each of these treatment options, the doctors address the importance of managing corresponding treatment side effects and adverse events, and recognize the need to control the high costs of treatment.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
ACA Dependent Coverage Extension and Young Adults’ Substance-Associated ED Visits
September 15th 2025This study examines the impact of the Affordable Care Act (ACA) on substance-associated emergency department (ED) visits among young adults, revealing reduced alcohol-associated visits but unchanged opioid-associated visits.
Read More